

June 11, 2019
 Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

**Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses)
 Issued by way of Third Party Allotment**

TOKYO, Japan, June 11, 2019—Symbio Pharmaceuticals Limited announces the large volume exercise of the 46th Stock Acquisition Rights, issued and allotted to EVO FUND on April 25, 2018, during the period from June 3, 2019 to June 11, 2019, as below.

(1)	Name of the stock acquisition rights	Symbio Pharmaceuticals Limited 46 th Stock Acquisition Rights
(2)	Number of issued shares from the beginning of this month	2,300,000 Shares
(3)	Number of stock acquisition rights being exercised from the beginning of this month and the ratio to the entire issue	2,300,000 Units (Ratio to the total number of stock acquisition rights issued 15,000,000 units : 15.33%)
(4)	Number of unexercised stock acquisition rights as of the beginning of this month	5,666,000 Units
(5)	Number of remaining unexercised stock acquisition rights as of today	3,366,000 Units

(6) Exercise status from the beginning of this month

Exercise Date	Number of delivered shares		Exercise Price (¥)	Number of stock acquisition rights being exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
June 3 (Mon.)	—	—	165	—
June 4 (Tue.)	500,000	—	162	500,000
June 6 (Wed.) to June 10 (Mon.)	—	—	162	—
June 11 (Tue.)	1,800,000	—	154	1,800,000

※Number of issued shares at the end of the previous month : 91,784,724 shares [of which 75 shares are treasury shares]

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.